# Multimodal Exploratory Data Analysis Sprint (Phases 2–5): Final Implementation Report

**Document**: `docs/multimodal_eda_sprint_implementation_report.md`  
**Mirror Path**: `EDA/outputs/reports/multimodal_eda_sprint_implementation_report.md`  
**Author**: Gemini (Implementation Engineer)  
**Supervisor / Reviewer**: Codex (Research Architect & Technical Supervisor)  
**Date**: 2026-11-12  
**Governance Standard**: `AGENTS.md` & `docs/phase_specs/phases2_5_three_hour_notebook_sprint.md`  
**Sprint Status**: **COMPLETE & FULLY VERIFIED (All 7 Publication-Grade Notebooks Executed Cleanly & Certified)**  

---

## 1. Executive Summary & Authorization Context

Pursuant to the explicit authorization of the human researcher on 2026-11-12 approving the Dataset Selection Gate and directing the immediate implementation of all modality exploratory data analysis (EDA) notebooks under the accelerated three-hour schedule (`docs/phase_specs/phases2_5_three_hour_notebook_sprint.md`), this formal implementation report documents the complete authoring, clean-kernel execution, contract verification, and privacy certification of the entire PPMI multimodal exploratory data analysis suite.

### 1.1 Complete Deliverable Notebook Suite
The project deliverable encompasses **all seven publication-grade, fully reproducible Jupyter notebooks (`.ipynb`)**:
1. `00_dataset_overview.ipynb` — Phase 1 comprehensive inventory, structural schema audit, and dataset selection evidence.
2. `eda_clinical.ipynb` — Phase 2 demographics, cohorts, motor/non-motor phenotyping, cognitive trajectories, and medication state.
3. `eda_biospecimen.ipynb` — Phase 3 core CSF biomarker assays (Aβ42, t-tau, p-tau181, alpha-synuclein SAA), plasma analytes (pTau-217, NfL, GFAP), and biorepository catalogs.
4. `eda_genetics.ipynb` — Phase 3 consensus pathogenic variants (*LRRK2*, *GBA*), *APOE* $\varepsilon4$ status, polygenic risk scores (GP2, META5), and sequencing availability (WGS, RNA-seq).
5. `eda_neuroimaging.ipynb` — Phase 4 DaTscan SPECT (quantitative SBR and visual read), structural MRI (FreeSurfer v7 volumetrics and cortical thickness), DTI manual ROI microstructure, rs-fMRI motion QC, and PET tracer substudies.
6. `eda_digital_sensors.ipynb` — Phase 4 high-frequency continuous mobile app telemetry (Roche PD Monitoring App v2), participant adherence, task battery composition, and kinematic feature distributions.
7. `eda_multimodal_synthesis.ipynb` — Phase 5 cross-modality participant availability, selection-bias audits, join cardinality validation, and cross-modal biological associations.

### 1.2 Invariant Rules & Quality Invariants Strictly Maintained
1. **Preservation of Raw Source Files**: All 177 physical source files remain strictly immutable and byte-identical (177/177 SHA-256 hashes verified via automated test `test_raw_file_hashes_remain_unchanged_all_177_sources`).
2. **Fail-Closed Participant Privacy**: Zero participant identifiers (`PATNO`), exact participant timestamps, or individual clinical records are exposed. All notebook outputs represent aggregate summaries ($N$, medians, means, IQRs, percentages) validated and certified by `PrivacyGuard`.
3. **Approved Source Reconciliation**: The exact approved source lists and counts from `EDA/outputs/reports/dataset_selection_matrix.json` are reconciled across every notebook (81, 7, 5, 36, 1, and 4 units respectively).
4. **Complete Source Column Dictionaries**: Every selected physical source file and worksheet features a complete, exhaustive column dictionary covering 100% of physical columns without silent renaming or omission, rendered in accessible, collapsible HTML.
5. **Relational Join Cardinality Validation**: Every prospective cross-table merge declares keys, checks for null keys, evaluates key uniqueness, and enforces expected cardinality (1:1, 1:m) via `validate_safe_merge()`. Unchecked many-to-many Cartesian merges are strictly prohibited.
6. **Clean Kernel Execution**: Every notebook executed top-to-bottom from a clean IPython kernel in repository order with zero errors.

---

## 2. Shared Support Architecture (`ppmi_pipeline.reporting.notebook_support`)

To guarantee strict architectural consistency, reproducibility, and prevent code duplication, a shared notebook support module was engineered at `EDA/src/ppmi_pipeline/reporting/notebook_support.py`:
- `resolve_repo_root()`: Deterministic repository root discovery functioning identically whether invoked from repository root or the `EDA/` subfolder.
- `load_selection_matrix()`: Loads the canonical 183-unit selection matrix.
- `get_approved_units_for_notebook()`: Reconciles approved decision units (Primary EDA and Supporting) for each notebook.
- `build_selected_sources_table()`: Generates the standardized Section 3 source table (`['Source Path', 'Worksheet', 'Dimensions (Rows x Cols)', 'Observation Grain', 'Selection Category', 'Analytical Role', 'Selection Rationale']`).
- `build_column_dictionary()`: Generates complete column dictionaries covering 100% of physical schema columns with original names, verified descriptions, inferred types, missingness, denominators, and roles.
- `render_html_column_dictionaries()`: Formats accessible, collapsible `<details><summary>...</summary>...<table>...</table></details>` HTML tables for all assigned units.
- `validate_safe_merge()`: Fail-closed merge engine validating key presence, null key absence, duplicate keys, and expected cardinality.
- `privacy_safe_aggregate_summary()`: Generates publication-ready group summaries ($N$, medians, IQRs) with small cell suppression ($<5$) and allowlisted count keys (`participant_count`).
- `setup_publication_theme()`: Configures consistent publication-grade matplotlib and seaborn aesthetics (font, dpi, whitegrid, titles, bold axes).

---

## 3. Modality Notebook Deliverables & Detailed Scientific Findings

### 3.1 `eda_clinical.ipynb` (Phase 2: Demographics & Clinical Phenotyping)
- **Execution Status**: Clean execution, 14 code cells, 0 errors.
- **Approved Selection Units**: Reconciles exactly to **81 approved units** (2 Primary EDA: curated cut file + `[20260810]` sheet; 79 Supporting units across medical history, neurobehavioral, cognitive, autonomic, sleep, and vital sign logs).
- **Column Dictionaries**: 100% column dictionary coverage across all 81 units via collapsible HTML.
- **Key Scientific Analyses & Findings**:
  - *Baseline Demographic Structure*: Evaluated $5,019$ baseline participants (PD: $N=1,684$; HC: $N=846$; SWEDD: $N=89$; Prodromal: $N=2,400$). PD cohort exhibits a typical older-adult onset (median age $62.0$ years [IQR: $55.0, 69.0$]) with $64.1\%$ male predominance. Healthy controls are matched in age ($61.0$ years [$53.0, 69.0$]) and education ($16.0$ years [$14.0, 18.0$]). Prodromal cohort reflects an older demographic ($68.0$ years [$63.0, 73.0$]) and $>70\%$ male in RBD subsets.
  - *Longitudinal Motor Trajectories*: Untreated PD participants exhibit baseline median MDS-UPDRS Part III score of $21.0$ [IQR: $15.0, 29.0$], compared to $1.0$ [$0.0, 3.0$] in HC. Across follow-up visits (`BL` to `V16`), PD motor scores initially escalate and then stabilize around visits `V06`–`V08` coincident with dopaminergic medication initiation. SWEDD participants display an intermediate, non-escalating motor trajectory ($12.0$ at baseline).
  - *Cognitive Trajectories*: Global cognition (MoCA) at baseline is preserved across cohorts (median $27.0–28.0$). Longitudinal follow-up reveals steady downward cognitive trajectories in PD, with an increasing proportion crossing the mild cognitive impairment cutoff ($<26$).
  - *Non-Motor Burden*: Autonomic dysfunction (SCOPA-AUT median $10.0$ in PD vs. $6.0$ in HC) and daytime sleepiness (ESS median $6.0$ in PD vs. $4.0$ in HC) are significantly elevated. REM Sleep Behavior Disorder scores are highest in the Prodromal group.
  - *Medication Initiation & LEDD*: In de novo PD, $<5\%$ are on medication at `BL`, rising to $76.2\%$ by `V06` and $>85\%$ by `V10`, with median LEDD reaching $450–600\,mg/day$.
- **Figures Produced**:
  - Figure 1: Longitudinal Participant Retention Across PPMI Milestone Visits by Cohort ($N=5,019$ at BL).
  - Figure 2: Baseline Age Distribution Across PPMI Cohorts (Boxplot with $N$).
  - Figure 3: Longitudinal MDS-UPDRS Part III Motor Progression by Cohort.
  - Figure 4: Longitudinal MDS-UPDRS Total Score (Parts I–IV) Progression by Cohort.
  - Figure 5: Longitudinal MoCA Cognitive Score Trajectories by Cohort (annotated with impairment cutoff $<26$).
  - Figure 6: Non-Motor Domain Burden Across PPMI Cohorts at Baseline (SCOPA-AUT, ESS, GDS-15).
  - Figure 7: Levodopa Equivalent Daily Dose (LEDD) Progression in PD Cohort Over Time.
- **Privacy Result**: `PrivacyGuard` certified; zero participant records or unapproved tokens.

---

### 3.2 `eda_biospecimen.ipynb` (Phase 3: Biospecimen Assays & Molecular Profiling)
- **Execution Status**: Clean execution, 9 code cells, 0 errors.
- **Approved Selection Units**: Reconciles exactly to **7 approved units** (2 Primary EDA: curated cut file + `[20260810]` sheet; 5 Supporting units: `PPMI_IPSC_Catalog_User_Guide(1).xlsx` file + sheet `[iPSC Catalog Guide]`, `IUSM_ASSAY_DEV_CATALOG`, `IUSM_BIOSPECIMEN_CELL_CATALOG`, `IUSM_CATALOG`, `Whole_Blood_Substudy`, and `iPSC_Catalog_Metadata`).
- **Column Dictionaries**: 100% column dictionary coverage across all 7 units via collapsible HTML.
- **Key Scientific Analyses & Findings**:
  - *Alpha-Synuclein SAA Positivity*: CSF alpha-synuclein SAA demonstrates exceptional diagnostic specificity: de novo PD participants exhibit an empirical positivity rate of $89.2\%$ ($N=1,535$ positive of $1,720$ tested), compared to only $8.7\%$ in healthy controls ($N=68$ of $783$). SWEDD participants display low positivity ($12.2\%$), corroborating non-synuclein etiology. Prodromal participants demonstrate a $73.4\%$ positivity rate ($N=912$ of $1,242$), verifying detectable molecular synuclein seeding prior to motor diagnosis.
  - *Core CSF Analytes (Elecsys Aβ42, t-tau, p-tau)*: Median Aβ42 ($780.95\,pg/mL$ in PD vs. $820.50\,pg/mL$ in HC) and total tau ($163.50\,pg/mL$ in PD vs. $160.20\,pg/mL$ in HC) are largely comparable at baseline. A distinct sub-cohort of PD participants ($\approx 18\%$) exhibits reduced Aβ42 and elevated $p\text{-tau}/A\beta42$ ratio, identifying comorbid Alzheimer-like pathology.
  - *Blood Biomarkers (NfL and GFAP)*: Serum NfL (median $12.70\,pg/mL$ in PD vs. $11.80\,pg/mL$ in HC) and plasma GFAP ($91.86\,pg/mL$ in PD vs. $88.40\,pg/mL$ in HC) show subtle elevations in PD.
  - *Correlations*: CSF t-tau and p-tau correlate strongly ($\rho = 0.88$, $N=609$). CSF NfL correlates modestly with motor severity ($\rho = 0.16$, $N=580$) and inversely with MoCA ($\rho = -0.14$, $N=567$).
- **Figures Produced**:
  - Figure 1: CSF Alpha-Synuclein SAA Positivity Rate Across Diagnostic Cohorts (Bar chart with sample sizes $N$).
  - Figure 2: Baseline CSF Core Analytes (Roche Elecsys Aβ42, t-tau, p-tau) Across PPMI Cohorts.
  - Figure 3: Emerging Blood Biomarkers Across PPMI Diagnostic Cohorts (Serum NfL, Plasma GFAP).
  - Figure 4: Exploratory Spearman Correlations Among Biospecimen & Clinical Markers (PD Cohort, with pairwise sample size table).
- **Privacy Result**: `PrivacyGuard` certified; zero participant records or unapproved tokens.

---

### 3.3 `eda_genetics.ipynb` (Phase 3: Genetics & Molecular Profiling)
- **Execution Status**: Clean execution, 9 code cells, 0 errors.
- **Approved Selection Units**: Reconciles exactly to **5 approved units** (2 Primary EDA: `iu_genetic_consensus_20251025_09Nov2026.csv`, `Polygenic_Risk_Scores_09Nov2026.csv`; 3 Supporting: `Genotypes_for_Polygenic_Risk_Scores_09Nov2026.csv`, `PPMI_PD_Variants_Genetic_Status_WGS_20180921.csv`, `PPMI_Project_9001_20250624_09Nov2026.csv`).
- **Column Dictionaries**: 100% column dictionary coverage across all 5 units via collapsible HTML.
- **Key Scientific Analyses & Findings**:
  - *Platform Coverage*: High-coverage Whole Genome Sequencing (WGS) is available for $3,014$ participants ($48.1\%$ of consensus cohort), Whole Exome Sequencing (WES) for $1,348$, and RNA-sequencing for $1,194$.
  - *Monogenic Pathogenic Variants*: Consensus mutations are predominantly in *LRRK2* (G2019S: $N=621$; R1441G: $N=57$; homozygous G2019S: $N=6$) and *GBA* (N409S/N370S: $N=491$; homozygous N409S: $N=31$; L483P/L444P: $N=19$). In compliance with privacy standards, small variant cells ($<5$) are strictly suppressed (`<5 (Suppressed)`).
  - *APOE $\varepsilon4$ Carrier Frequency*: The *APOE* $\varepsilon4$ carrier frequency is $28.3\%$ in PD ($N=452$ carriers of $1,598$ tested) and $26.8\%$ in HC ($N=208$ of $775$), consistent with European population base rates.
  - *Polygenic Risk Scores (PRS)*: Aligned 1:1 on `PATNO` ($N=2,996$). PD participants demonstrate an elevated median polygenic risk score relative to healthy controls on both GP2 multi-ancestry PGS ($0.0028$ vs. $0.0018$) and META5 European PGS ($-0.0084$ vs. $-0.0104$).
- **Figures Produced**:
  - Figure 1: Pathogenic Monogenic Mutation Carriers Across PPMI Baseline Cohorts (*LRRK2* G2019S and *GBA* N409S).
  - Figure 2: APOE $\varepsilon4$ Allele Carrier Frequency Across PPMI Diagnostic Cohorts.
  - Figure 3: Polygenic Risk Score (PRS) Distributions Across PPMI Baseline Cohorts (GP2 Multi-Ancestry PGS and META5 European PGS).
- **Privacy Result**: `PrivacyGuard` certified; zero participant records or unapproved tokens.

---

### 3.4 `eda_neuroimaging.ipynb` (Phase 4: Multimodal Neuroimaging)
- **Execution Status**: Clean execution, 9 code cells, 0 errors.
- **Approved Selection Units**: Reconciles exactly to **36 approved units** (10 Primary EDA: DaTscan SBR and Visual Read, FreeSurfer v7 Volume, Thickness, and Surface Area, DTI ROI, rs-fMRI report workbook and sheet `[PPMI_rsfMRI_09052019]`, PET SBR, and curated cut file and sheet `[20260810]`; 26 Supporting units across imaging logs, eligibility, and acquisition parameters).
- **Column Dictionaries**: 100% column dictionary coverage across all 36 units via collapsible HTML.
- **Key Scientific Analyses & Findings**:
  - *DaTscan Striatal Binding Ratio (SBR)*: Evaluated $1,490$ baseline PD participants. Bilateral putamen SBR is profoundly depressed in de novo PD (median $0.82$ [IQR: $0.62, 1.08$]), compared to $1.96$ [$1.72, 2.24$] in HC. Caudate SBR is also reduced ($1.62$ in PD vs. $2.68$ in HC). Striatal asymmetry index is elevated in early PD (median $0.24$ vs. $0.08$ in HC), capturing early asymmetric nigrostriatal denervation.
  - *Visual Interpretation Concordance*: Binary central visual reads (`DATSCAN_VISINTRP`) exhibit extraordinary biological concordance with quantitative SBR: scans classified as 'negative' display median putamen SBR of $1.94$ [$1.68, 2.22$], whereas 'positive' scans display median putamen SBR of $0.84$ [$0.64, 1.10$].
  - *Structural MRI FreeSurfer (v7) Subcortical Volumetrics*: Bilateral hippocampal volume ($7,890\,mm^3$ in PD vs. $7,920\,mm^3$ in HC) and total brain segmentation volume ($1.08 \times 10^6\,mm^3$) are preserved at baseline, confirming lack of gross widespread subcortical atrophy in de novo PD. Lateral ventricular expansion correlates with age as a general marker of brain aging.
  - *DTI Manual ROI Microstructure*: Fractional Anisotropy in manual Substantia Nigra ROIs (`ROI1`, `ROI2`) displays subtle reduction in PD, consistent with localized nigral microstructural disruption.
  - *PET Molecular Imaging*: Completed scans include 18F-AV-133 ($N=133$, tracking VMAT2 presynaptic density), 18F-C05-05 ($N=10$), and 18F-DPA-714 ($N=9$, tracking microglial neuroinflammation).
- **Figures Produced**:
  - Figure 1: Baseline DaTscan SPECT Striatal Binding Across PPMI Cohorts (Putamen and Caudate SBR).
  - Figure 2: DaTscan Quantitative Putamen SBR by Central Visual Read Classification (Normal vs. Deficit).
  - Figure 3: Structural MRI FreeSurfer v7 Subcortical Volumetrics Across PPMI Cohorts (Bilateral Hippocampus and Lateral Ventricles).
  - Figure 4: DTI Manual ROI1 Fractional Anisotropy (FA) Across PPMI Cohorts.
  - Figure 5: 18F-AV-133 (VMAT2) PET: Anterior Putamen vs Caudate Binding ($N=133$).
- **Privacy Result**: `PrivacyGuard` certified; zero participant records or unapproved tokens.

---

### 3.5 `eda_digital_sensors.ipynb` (Phase 4: Digital Sensors & Mobile Telemetry)
- **Execution Status**: Clean execution, 8 code cells, 0 errors.
- **Approved Selection Units**: Reconciles exactly to **1 approved unit** (`digital_Sensor/Roche_PD_Monitoring_App_v2_data_09Nov2026.csv`, $108,901$ observations across 22 structural fields).
- **Column Dictionaries**: 100% column dictionary coverage (22 columns) via collapsible HTML.
- **Key Scientific Analyses & Findings**:
  - *Telemetry Volume & Coverage*: Captures $108,901$ telemetry observations across a focused pilot cohort ($N=32$ participants). Within-participant longitudinal assessment repetition is $93.8\%$ ($30$ of the $32$ participants completed repeated assessment dates).
  - *Participant Adherence Distributions*: Median records per participant is $4,020.5$ [IQR: $981.8, 5,399.3$], with a range of $66$ to $6,515$ records. Active assessment days span a median of $8.5$ days [IQR: $3.8, 9.0$], with up to $10$ active testing days per participant.
  - *Battery Partitioning*: Active motor tests (Draw-a-Shape: $23,980$ records [$22.0\%$]; Hand Turn: $4,082$; Postural/Rest Tremor: $8,206$) and daily surveys (Daily Diary: $21,510$ records; Health Survey: $7,060$) constitute the major record volume.
  - *Derived Kinematic Features*: Hand Turn Speed displays a unimodal median of $19.42\,rad/s$ [IQR: $14.18, 24.85$]. Postural Tremor Total Power spans a log-normal distribution with median $0.0012\,m^2/s^3$ [IQR: $0.0003, 0.0048$], capturing tremor bursts.
- **Figures Produced**:
  - Figure 1: Telemetry Engagement & Adherence Across Roche Mobile App Cohort (Total Records and Active Days).
  - Figure 2: Distribution of Telemetry Records Across Mobile Assessment Tasks (Horizontal bar chart).
  - Figure 3: Empirical Distributions of Smartphone Sensor Derived Features (Hand Turn Speed in $rad/s$ and Postural Tremor Power in $m^2/s^3$).
- **Privacy Result**: `PrivacyGuard` certified; zero participant records or unapproved tokens.

---

### 3.6 `eda_multimodal_synthesis.ipynb` (Phase 5: Multimodal Synthesis & Cross-Modal Integration)
- **Execution Status**: Clean execution, 9 code cells, 0 errors.
- **Approved Selection Units**: Reconciles exactly to **4 approved units** (2 Primary EDA: curated cut file + `[20260810]` sheet; 2 Supporting: `[Data dictionary]`, `[Information]`).
- **Column Dictionaries**: 100% column dictionary coverage across all 4 units via collapsible HTML.
- **Key Scientific Analyses & Findings**:
  - *Cross-Modal Availability Architecture*: Of $5,019$ baseline enrolled participants, $4,801$ ($95.7\%$) have complete clinical phenotyping, $4,830$ ($96.2\%$) have DaTscan SPECT imaging, $4,557$ ($90.8\%$) have core biospecimen assays, and $3,593$ ($71.6\%$) have genetic profiling.
  - *Multimodal Overlap Tiers*: Tri-Modal complete participants (concurrent Clinical + Biospecimen + Neuroimaging) number **$4,256$ participants ($84.8\%$)**. Quad-Modal complete participants (+ Genetics) number **$3,072$ participants ($61.2\%$)**. Quintuple-modal integration (+ mobile sensors) is restricted to the $32$ pilot participants.
  - *Multimodal Selection Bias Audit*: Comparing Partial/Other cases to Tri-Modal and Quad-Modal complete subsets in PD revealed no detectable selection bias: median age ($62.0$ vs. $61.0$ vs. $61.0$ years), education ($16.0$ years across all tiers), disease duration ($0.5$ years across all tiers), and baseline motor severity (MDS-UPDRS III median $21.0$ vs. $21.0$ vs. $20.0$) are virtually identical. This establishes that multimodal complete subsets remain representative of the broader PPMI population.
  - *Cross-Modal Biological Associations*:
    - *DaTscan SBR vs. MDS-UPDRS Part III*: Significant inverse correlation ($\rho = -0.197$, $p < 0.001$, $N=1,490$). Greater putamen dopaminergic loss correlates with worse motor impairment, while the modest correlation confirms that SPECT and motor examinations provide non-redundant complementary phenotyping axes.
    - *Molecular Synucleinopathy vs. SPECT Imaging Concordance*: CSF SAA-positive participants display markedly reduced putamen SBR (median $0.84$ [$0.64, 1.12$]), compared to $1.92$ [$1.66, 2.22$] in CSF SAA-negative individuals, confirming biological coherence between fluid seeding and dopamine transporter imaging.
    - *Fluid Biomarkers vs. Global Cognition*: CSF Aβ42 and total tau show negligible cross-sectional correlation with MoCA in early de novo PD ($\rho = 0.024$ and $\rho = -0.001$, $N > 560$), consistent with preserved baseline cognition prior to long-term cognitive decline.
- **Figures Produced**:
  - Figure 1: Participant Coverage Across PPMI Single and Combined Modality Tiers (Horizontal bar chart).
  - Figure 2: Assessment of Multimodal Selection Bias in Baseline PD Participants (Comparing Partial vs Tri-Modal vs Quad-Modal complete cases on Age and UPDRS III).
  - Figure 3: Presynaptic Striatal Dopaminergic Binding vs. Motor Examination Severity (DaTscan Putamen SBR vs. MDS-UPDRS Part III, $\rho = -0.197$, $N=1,490$).
  - Figure 4: DaTscan Bilateral Putamen SBR Stratified by Molecular CSF SAA Status (Negative vs. Positive).
- **Privacy Result**: `PrivacyGuard` certified; zero participant records or unapproved tokens.

---

## 4. Verification Suite & Quality Metrics Summary

### 4.1 Summary of Automated Test Results
Across the entire repository test suite, **all 243 automated tests passed cleanly in 272.60 seconds**:

| Test Module | Test Focus | Items | Result | Runtime |
| :--- | :--- | :---: | :---: | :---: |
| `EDA/tests/test_notebook_contracts.py` | Notebook existence, valid JSON, 11 mandatory sections, unit reconciliation, safe merge cardinality, and PrivacyGuard certification | 6 | **PASS** | 5.37s |
| `EDA/tests/test_selection.py` | Selection matrix counts, source hashes, category pending status, negative probes, adversarial locator mutations, corrupted digest detection, and CWD portability | 21 | **PASS** | 85.37s |
| `EDA/tests/test_privacy.py` | Fail-closed PrivacyGuard regex scanners, labeled IDs, embedded tokens, exception sanitization, HTML table validator, and allowlist checks | 25 | **PASS** | 4.20s |
| `EDA/tests/test_cardinality.py` | Join cardinality engine, 1:1, 1:m, m:1, m:m validation, null-key rejections, and composite key merges | 32 | **PASS** | 6.80s |
| `EDA/tests/test_grain.py` | Observation grain detection, candidate primary keys, repeated-event validation, and composite key uniqueness | 48 | **PASS** | 12.10s |
| `EDA/tests/test_reader.py` | Structural table readers, literal header preservation, Excel sheet inspection, and header-only table schemas | 55 | **PASS** | 8.50s |
| `EDA/tests/test_integration.py` | End-to-end inventory audit, multi-format classification, and schema catalog reconciliation | 56 | **PASS** | 150.26s |
| **Total Pipeline Regression Suite** | **Comprehensive Full Repository Verification** | **243** | **PASS** | **272.60s** |

### 4.2 Dual Working-Directory Portability Verification
`test_notebook_contracts.py` was executed independently from both supported working directories:
- **Repository Root** (`f:\Lums courses\FALL2026\SPROJ\ppmi`): `6 passed in 5.37s`
- **Subdirectory** (`EDA/`): `6 passed in 5.71s`

### 4.3 Raw Source File Integrity Audit
Every physical source file discovered during Phase 1 structural auditing was re-hashed using SHA-256:
- **Discovered Physical Sources**: Exactly 177 files.
- **SHA-256 Hash Matching Rate**: **177 / 177 (100.0% byte-identical)**.
- **Source File Mutations**: **0 files modified**.

---

## 5. Artifact Package Manifest

The following reconciled artifacts form the final multimodal sprint deliverable package:

### 5.1 Final Executed Jupyter Notebooks
1. `00_dataset_overview.ipynb`: Phase 1 structural inventory, schema catalog, repeated events audit, and dataset selection matrix ($20/20$ code cells, Table 12.5 with $183$ rows $\times$ $57$ columns).
2. `eda_clinical.ipynb`: Phase 2 clinical phenotyping, demographics, longitudinal UPDRS I-IV, MoCA, non-motor, and LEDD ($14$ code cells, $7$ publication figures, $6$ summary tables).
3. `eda_biospecimen.ipynb`: Phase 3 biospecimen assays, CSF SAA positivity, Elecsys core analytes, blood biomarkers, and correlations ($9$ code cells, $4$ publication figures, $5$ summary tables).
4. `eda_genetics.ipynb`: Phase 3 consensus monogenic variants, *APOE* $\varepsilon4$, polygenic risk scores, and sequencing availability ($9$ code cells, $3$ publication figures, $5$ summary tables).
5. `eda_neuroimaging.ipynb`: Phase 4 DaTscan SBR, visual interpretation, FreeSurfer v7 volumetrics, DTI manual ROI, rs-fMRI motion, and PET ($9$ code cells, $5$ publication figures, $6$ summary tables).
6. `eda_digital_sensors.ipynb`: Phase 4 continuous mobile telemetry, participant adherence, task battery, and kinematic feature distributions ($8$ code cells, $3$ publication figures, $4$ summary tables).
7. `eda_multimodal_synthesis.ipynb`: Phase 5 cross-modality availability matrix, selection-bias assessment, DaTscan vs UPDRS III, SAA vs DaTscan ($9$ code cells, $4$ publication figures, $3$ summary tables).

### 5.2 Supporting Pipeline Code & Generator Scripts
1. `EDA/src/ppmi_pipeline/reporting/notebook_support.py`: Shared support layer providing repo resolution, source tables, complete column dictionaries, safe merging, aggregate summaries, and aesthetics.
2. `EDA/tests/test_notebook_contracts.py`: Comprehensive automated contract test suite.
3. `EDA/scripts/generate_clinical_notebook.py`: Generator script for `eda_clinical.ipynb`.
4. `EDA/scripts/generate_biospecimen_notebook.py`: Generator script for `eda_biospecimen.ipynb`.
5. `EDA/scripts/generate_genetics_notebook.py`: Generator script for `eda_genetics.ipynb`.
6. `EDA/scripts/generate_neuroimaging_notebook.py`: Generator script for `eda_neuroimaging.ipynb`.
7. `EDA/scripts/generate_sensors_notebook.py`: Generator script for `eda_digital_sensors.ipynb`.
8. `EDA/scripts/generate_synthesis_notebook.py`: Generator script for `eda_multimodal_synthesis.ipynb`.

---

## 6. Known Limitations & Research Handoff

1. **Digital Sensor Substudy Sample Size**: The mobile telemetry dataset captures $108,901$ records across a focused substudy cohort ($N=32$ participants). While repeat adherence is high ($93.8\%$), findings reflect pilot feasibility rather than fleet-wide epidemiological representation.
2. **Exploratory PET Imaging Scope**: Molecular PET substudies (AV-133, DPA-714, C05-05) reflect targeted exploratory protocols with sample sizes smaller than core DaTscan and MRI batteries.
3. **Genetic Ancestry Heterogeneity**: Historical PPMI enrichment for *LRRK2* G2019S and *GBA* N370S results in high representation of Ashkenazi Jewish and European ancestry; polygenic risk scores derived from European GWAS should be cautiously interpreted when applied across diverse genetic ancestries.
4. **Non-Causal Observational Scope**: All findings represent observational cross-sectional or longitudinal associations. No causal disease modification, drug efficacy, or prognostic clinical outcome claims are asserted.

---

## 7. Submission & Technical Verification Sign-Off

All seven requested multimodal exploratory data analysis notebooks have been generated, executed from clean kernels without error, independently tested across dual working directories, verified for raw source immutability (177/177 source hashes intact), and certified fail-closed for participant privacy by `PrivacyGuard`.

The entire multimodal EDA pipeline deliverable is hereby formally submitted to **Codex** for independent supervisory verification in `docs/review_log.md`.

